July 18, 2025 4:54pm

As I had written this a.m., “They’re coming, “uncle algo and his electronic trading dwarfs” are thirsting for profiting. Will it be a whack-a-share sort of day after reviewing the depreciating price action with IBB, XBI and VIX metrics?”

News: Generation Bio (GBIO -$0.1162 or -22.29% to $0.41) will implement a 1-for-10 reverse stock split (RSS) of the issued shares of the stock effective at 5:00 pm ET on 7/21/25. The goal of the RSS is to increase the per-share market price to enable regaining compliance for continued listing on the Nasdaq

Whack-a-mole stock, Harvard Apparatus RT (OTCQB: HRGN) dives -$0.06 to $1.55 with 3,636 shares traded, I guess Beijing, China is NOT dropping any $’s to shore-up their lack of cash and runway <52-week range $0.935 to $5.90 and 7 sessions in July and 12 in June of no volume> pump the volume to avoid the decline - A Ponzi scheme while management team pulls down some massive salaries and bonuses!

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Friday’s RegMed Investors’ (RMi) pre-open: De-risk … https://www.regmedinvestors.com/articles/14003

Thursday night’s RegMed Investors (RMi) Closing Bell: An econs good, the newest market miracle … https://www.regmedinvestors.com/articles/14002

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Friday: The Dow closed DOWN -142.30 points or -0.323%, the S&P closed DOWN -0.547 points or -0.01% while the Nasdaq closed UP +10.01 points or +0.05%

  • Theme of the session, a drop in consumers’ fears about tariff-induced inflation down to their lowest levels since February

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • The University of Michigan’s Survey of Consumers for July showed overall sentiment rose 1.8% from June to 61.8, exactly in line with the estimate and at the highest since February.
  • A 1-year inflation forecast plunged to 4.4%, down from 5% in June and well off the 6.6% level in May, which was the highest reading since late 1981. For the 5-year outlook, the expectation slid to 3.6%, down 0.4% point from June.

Friday’s advance/decline line opened negative with 14 incliners, 15 decliners and 6 flats ending with a negative close of 10 incliners, 21 decliners and 4 flats  

Metrics:  Friday, the IBB was down -2.01%, the XBI was down -1.85 % while the VIX was down -0.11 points or -0.67% at 16.41

 

Q3 – 7/25 – 1 market holiday, 9 positive and 4 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Friday Closing UP (10 of 10)

  • CRISPR Therapeutics (CRSP +$10.04),
  • Mesoblast (MESO +$3.28 after Thursday’s +$0.78 after Wednesday’s +$0.39),
  • Solid Biosciences (SLDB +$0.60 after Thursday’s +$0.21),
  • Beam Therapeutics (BEAM +$0.30 after Thursday’s +$0.38, Wednesday’s +$0.51 and Tuesday’s -$1.59),
  • Intellia Therapeutics (NTLA +$0.23 after Thursday’s -$0.13 after Wednesday’s +$0.53),
  • Prime Medicine (PRME +$0.23 after Thursday’s -$0.14 after Wednesday’s -$0.25),
  • Caribou Biosciences (CRBU +$0.22),
  • Editas Medicine (EDIT +$0.03),
  • Sangamo Therapeutics (SGMO +$0.0273),
  • Voyager Therapeutics (VYGR +$0.02 after Thursday’s -$0.05),

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Brainstorm Cell Therapeutics (BCLI)
  • Homology Medicine (FIXX)

Friday’s Closing DOWN (10 of 21):

  • Alnylam Pharmaceuticals (ALNY -$4.16 after Thursday’s +$1.88, Wednesday’s +$11.50, Tuesday’s -$4.63 and Monday’s +$0.81),
  • Ultragenyx (Pharmaceuticals (RARE -$1.10),
  • Moderna (MRNA -$0.94 after Thursday’s +$0.14, Wednesday’s +$0.52, Tuesday’s -$1.29 and Monday’s -$0.77),
  • Vericel (VCEL -$0.92 after Thursday’s -$0.86),
  • Lenz Therapeutics (LENZ -$0.84 after Thursday’s -$0.62, Wednesday’s +$2.44, Tuesday’s -$0.98 and Monday’s -$0.96),
  • BioLife Solutions (BLFS -$0.59 after Thursday’s +$0.38 and Wednesday’s -$1.24),
  • Agenus (AGEN -$0.57 after Thursday’s +$0.36),
  • Regenxbio (RGNX -$0.53 after Thursday’s +$0.19),
  • Ionis Pharmaceuticals (IONS -$0.41 after Thursday’s -$0.60 and Wednesday’s +$0.84),
  • AxoGen (AXGN -$0.35 after Thursday’s -$0.19),

 

The BOTTOM LINE:  TGIF, the cocktail hour will be advanced!

Indexes slipped lower Friday after President Trump “reportedly” pushed for greater tariffs on the European Union.

  • “Trump is demanding a minimum tariff of between 15% and 20% in any deal with the EU, the Financial Times reported, citing three people briefed on the talks. The EU is attempting to reach a trade deal with the U.S. ahead of Trump’s Aug. 1 deadline, when Trump has vowed to begin implementing 30% tariffs on the bloc.” <CNBC>

 

Earnings are a’comin: 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA)

 

Cell and gene therapy sector equities stayed Thursday within the upside suffering a few downside flips after popping on Wednesday following a dive on Tuesday post Monday’s positive sector close …

  • After popping on Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….
  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

As I also wrote, the “June Swoon” is over … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

Last session of June as July evolves ‘25: understand the “flow” …

  • 7/18 – Friday closed negative with10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

Last week:

  • 7/11 - Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Friday: CRISPR Therapeutics (CRSP), Mesoblast (MESO) and Solid Biosciences (SLDB)
  • Thursday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Mesoblast (MESO)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
  • Tuesday: Harvard Apparatus RT (OTCQB: HRGN), Compass Therapeutics (CMPX) and Brainstorm Cell Therapeutics (BCLI)
  • Monday: Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY) and Cellectis SA (CLLS)

The worst three (3) in the session: 

  • Friday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Ultragenyx Pharmaceuticals RARE)
  • Thursday: Vericel (VCEL), Lenz Therapeutics (LENZ) and Ionis Pharmaceuticals (IONS)
  • Wednesday: Prime Medicine (PRME), Cellectis SA (CLLS) and Sage Therapeutics (SAGE)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vericel (VCEL)
  • Monday: Lenz Therapeutics (LENZ), Moderna (MRNA)and CRISPR Therapeutics (CRSP)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.